Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera. Rami Komrokji, M.D.: Once we ...

• Hgb > 18.5 g/dl (men) or > 16.5 g/dl (women) or Hgb or Hct > 99th percentile of method-specific reference range for age, sex or altitude of residence or Hgb > 17 g/dl (men) or > 15 g/dl (women) if ...

Major causes of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET) are represented by thrombosis and bleeding, progression to myelofibrosis and transformation to ...

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...

More than half of patients with polycythemia vera and essential thrombocythemia experienced partial molecular response after treatment with hydroxyurea, according to study results. Researchers from ...

Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia Authors: Luciana Teofili, Maurizio Martini, Myriam Luongo, Antonella Di Mario, Giuseppe Leone, Valerio De Stefano, and ...

This was the first prospective study of the incidence, causes, and effects of nonadherence to oral and injectable cytoreductive and/or antithrombotic treatments for PV and ET. Patients who were ...

Rami Komrokji, M.D.: Once we establish a diagnosis, our next step is thinking of the risk of a disease, because as you mentioned, those diseases are serious, but the risks vary. Maybe you can tell us ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...